Metropolitan Life Insurance CO Taysha Gene Therapies, Inc. Transaction History

Metropolitan Life Insurance CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$5.22 - $11.86 $38,001 - $86,340	-7,280 Closed	0 $0
Q4 2021 Jun 21, 2023	BUY	$11.43 - $19.2 $83,210 - $139,776	7,280 New	7,280 $84,000
Q3 2021 Jun 21, 2023	BUY	$15.82 - $21.57 $115,169 - $157,029	7,280 New	7,280 $135,000
Q2 2021 Mar 30, 2023	BUY	$19.29 - $26.38 $140,431 - $192,046	7,280 New	7,280 $154,000
Q2 2021 Aug 16, 2021	BUY	$19.29 - $26.38 $140,431 - $192,046	7,280 New	7,280 $154,000

118

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $72.5M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.